Laurus Labs appears in the short covering list with LTP 1875, down 1.99%, and OI change of 24.76%.
Read this note →Laurus Labs Limited
NSE LAURUSLABS BSE 540222 INE947Q01028
0 filings · 0 analysed
2,454.00
+3.30%
over today
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| Sharekhan (Mirae Asset Sharekhan) | 14 Oct 2026, 16:23 | short | 2,036.90 | 1,960.00 | 1,970.00 | 87% | hit |
| HDFC Securities | 07 Oct 2026, 15:25 | short | 2,052.80 | 1,580.00 | 2,340.00 | -61% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report lists Laurus Labs among top short-covering stocks with OI change of 24.76% and a 1.99% price decline.
Read this note →The report shows Laurus Labs in short covering (29 Sep expiry, price down 1.99%, OI up 24.76%) and in long unwinding (27 Oct expiry, price down 2.88%, OI down 2.79%).
Read this note →The Momentum Swing section lists a SELL call on LAURUSLABS October futures with targets 1990 and 1960, currently at +0.02% P/L.
Read this note →The Momentum Swing section lists a Sell call on Laurus Labs October futures with stop loss 2070.00 and targets of 1990.00 and 1960.00.
Read this note →The note lists Laurus Labs at 1,875 (-1.99%) with OI up 24.76% and an intraday range of 1,842.50-1,915.00.
Read this note →The report expects 26% YoY revenue growth and 55% YoY EBITDA growth driven by Small Molecule CDMO, naming it a strong performer despite its REDUCE rating.
Read this note →Listed as a technical stock on radar with a consolidation breakout on the daily chart, holding above 20 DEMA, with immediate support at 1,988.
Read this note →The note lists Laurus Labs with OI up 24.76% and LTP 1,875 (-1.99%), support 1,842.50 and resistance 1,915.00.
Read this note →The note lists Laurus Lab among stocks showing a positive derivatives setup.
Read this note →The report expects Laurus to deliver EBITDA growth of 53% YoY and PAT growth of 65% YoY, among the top outperformers in the healthcare pack.
Read this note →The technical snapshot lists Laurus Labs as a bullish intraday call with CMP 1958, support 1938 and resistance 1997.
Read this note →The report lists Lauras Lab as a stock to watch likely to show relative strength given Pharma's strong technical structure.
Read this note →The factsheet discloses Laurus Labs as the second-largest unhedged position of the Equity Ex-Top 100 fund at 7.11% of NAV.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief